Drug profile · INN
avacincaptad pegol sodium
IZERVAY
avacincaptad pegol sodium (IZERVAY) is a complement c5 inhibitor. Route of administration: intravitreal. Current US regulatory status: approved.
Drug details — avacincaptad pegol sodium
- US status
- approved
- Class
- —
- Route
- INTRAVITREAL
- Patents
- 0
- Programs
- 0
- Data quality
- 0.84
Quick answer
avacincaptad pegol sodium (IZERVAY) is a complement c5 inhibitor. Route of administration: intravitreal. Current US regulatory status: approved.
Key facts
Mechanism of action
Complement C5 inhibitor
Primary target: Complement C5
Approval history
| Authority | Status | Date |
|---|---|---|
| FDA | approved | — |
Related & competitor drugs
Frequently asked questions
What is avacincaptad pegol sodium?
avacincaptad pegol sodium (IZERVAY) is a complement c5 inhibitor. Route of administration: intravitreal. Current US regulatory status: approved.
What is the brand name for avacincaptad pegol sodium?
IZERVAY is a marketed brand name for avacincaptad pegol sodium. Check FDA Drugs@FDA for the current US label holder and prescribing information.
What is the US approval status of avacincaptad pegol sodium?
avacincaptad pegol sodium has approved status in the United States according to our Drugs@FDA-derived records. Verify on the official FDA label before clinical or commercial decisions.